No Data
No Data
Press Release: Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company fo
Anti-Obesity Drugs Global Strategic Business Report 2024-2030 Featuring F. Hoffmann-La Roche, GlaxoSmithKline, Eisai, Novo Nordisk, Rhythm Pharmaceuticals, and VIVUS - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Anti-Obesity Drugs Market to Reach $4.8 Billion b
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.
Maintaining Buy Rating on Rhythm Pharmaceuticals: Positive Outlook Amidst Growth and Upcoming Catalysts
No Data